ProShare Advisors LLC Acquires 6,119 Shares of Zoetis Inc. $ZTS

ProShare Advisors LLC raised its stake in Zoetis Inc. (NYSE:ZTS) by 5.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 115,215 shares of the company’s stock after buying an additional 6,119 shares during the period. ProShare Advisors LLC’s holdings in Zoetis were worth $8,045,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently modified their holdings of the company. Flossbach Von Storch SE acquired a new position in shares of Zoetis in the 2nd quarter worth $302,601,000. BlackRock Inc. lifted its holdings in shares of Zoetis by 10.8% during the second quarter. BlackRock Inc. now owns 39,430,181 shares of the company’s stock valued at $2,833,453,000 after purchasing an additional 3,845,869 shares during the last quarter. Ruane Cunniff & Goldfarb L.P. purchased a new stake in shares of Zoetis during the first quarter valued at $286,660,000. Southpoint Capital Advisors LP lifted its holdings in shares of Zoetis by 340.0% during the first quarter. Southpoint Capital Advisors LP now owns 2,200,000 shares of the company’s stock valued at $260,062,000 after purchasing an additional 1,700,000 shares during the last quarter. Finally, Carmignac Gestion acquired a new position in shares of Zoetis in the 2nd quarter valued at $113,230,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

Shares of ZTS stock opened at $88.60 on Thursday. Zoetis Inc. has a fifty-two week low of $68.77 and a fifty-two week high of $132.49. The stock’s 50-day moving average is $75.50 and its two-hundred day moving average is $93.03. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The firm has a market cap of $36.61 billion, a P/E ratio of 14.60, a PEG ratio of 1.23 and a beta of 0.67.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%. The firm’s revenue was down .2% on a year-over-year basis. During the same period in the previous year, the company earned $1.76 EPS. Analysts predict that Zoetis Inc. will post 6.15 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, October 30th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.4%. The ex-dividend date of this dividend is Friday, October 30th. Zoetis’s dividend payout ratio (DPR) is presently 34.93%.

Analyst Ratings Changes

ZTS has been the topic of a number of analyst reports. Weiss Ratings raised Zoetis from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, October 29th. Zacks Research upgraded Zoetis from a “strong sell” rating to a “hold” rating in a report on Monday, October 26th. Piper Sandler reduced their price objective on shares of Zoetis from $90.00 to $80.00 and set a “neutral” rating for the company in a research note on Monday, August 10th. BTIG Research dropped coverage on shares of Zoetis in a report on Friday, October 30th. They issued a “buy” rating for the company. Finally, Citigroup dropped their target price on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a research report on Tuesday, August 11th. Six investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $93.79.

Zoetis Profile

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company’s product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.